Mayer-Davis EJ, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med. 2017;376(15):1419–29.
Article PubMed PubMed Central Google Scholar
Xie J, et al. Global burden of type 2 diabetes in adolescents and young adults, 1990–2019: systematic analysis of the Global Burden of Disease Study 2019. BMJ. 2022;379:E072385.
Article PubMed PubMed Central Google Scholar
Saeedi P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Prac. 2019;157:107843.
Williams R, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020;162:108072.
Briggs AHD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15(6):835–42.
Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making. 2006;26(5):434–46.
Article CAS PubMed Google Scholar
Bojke LM, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health. 2009;12(5):739–49.
Frederix G, et al. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics. 2014;32(1):47–61.
Le QA. Structural uncertainty of Markov models for advanced breast cancer: a simulation study of lapatinib. Med Decis Making. 2016;36(5):629–40.
Silva-Illanes N, Espinoza M. Critical analysis of Markov models used for the economic evaluation of colorectal cancer screening: a systematic review. Value Health. 2018;21(7):858–73.
Von Schéele B, et al. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):235–57.
Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ. 2010;19(1):43–55.
Palmer AJ, et al. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care. 2007;30(6):1638–46.
Palmer AJBM. Computer modeling of diabetes and its complications: a report on the fifth mount hood challenge meeting. Value Health. 2013;16(4):670–85.
Tew M, et al. Exploring structural uncertainty and impact of health state utility values on lifetime outcomes in diabetes economic simulation models: findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. Med Decis Making. 2022;42(5):599–611.
Tarride J-E, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics. 2010;28(4):255–77.
Yi Y, et al. Economic models in type 2 diabetes. Curr Med Res Opin. 2010;26(9):2105–18.
Article CAS PubMed Google Scholar
Charokopou M, et al. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. Curr Med Res Opin. 2016;32(2):207–18.
Article CAS PubMed Google Scholar
Henriksson M, et al. A systematic review of cost-effectiveness models in type 1 diabetes mellitus. Pharmacoeconomics. 2016;34(6):569–85.
Li J, et al. Decision models in type 2 diabetes mellitus: a systematic review. Acta Diabetol. 2021;58(11):1451–69.
Article PubMed PubMed Central Google Scholar
Usman M, et al. Cost-effectiveness of intensive interventions compared to standard care in individuals with type 2 diabetes: a systematic review and critical appraisal of decision-analytic models. Diabetes Res Clin Pract. 2020;161:108073–108073.
Asche CV, Hippler SE, Eurich DT. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics. 2014;32(1):15–27.
Ogurtsova K, et al. External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement-a protocol for a systematic review. Syst Rev. 2017;6(1):267–267.
Article PubMed PubMed Central Google Scholar
Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):B2535-b2535.
Article PubMed PubMed Central Google Scholar
Karagiannidou M, et al. Systematic literature review of methodologies and data sources of existing economic models across the full spectrum of Alzheimer’s disease and dementia from apparently healthy through disease progression to end of life care: a systematic review protocol. BMJ Open. 2018;8(6):E020638-e020638.
Article PubMed PubMed Central Google Scholar
Philips Z, et al. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics. 2006;24(4):355–71.
Caro JJMFF, et al. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(6):796–803.
Palmer AJ, et al. Computer modeling of diabetes and its transparency: a report on the Eighth Mount Hood Challenge. Value Health. 2018;21(6):724–31.
Article PubMed PubMed Central Google Scholar
Popay J, et al. Guidance on the conduct of narrative synthesis in systematic reviews: a product from the ESRC Methods Progreamme. J Epidemiol Commut Health 2006;59(Suppl.1):A7.
Hayes AJ, et al. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925–33.
Article CAS PubMed Google Scholar
Lundqvist A, et al. Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations. PLoS ONE. 2014;9(10):E110235-e110235.
Article PubMed PubMed Central Google Scholar
Viriato D, et al. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. J Med Econ. 2014;17(7):499–507.
Van der Heijden AAWA, et al. Policy evaluation in diabetes prevention and treatment using a population-based macro simulation model: the MICADO model. Diabet Med. 2015;32(12):1580–7.
Wolowacz S, et al. Development and validation of a cost-utility model for type 1 diabetes mellitus. Diabet Med. 2015;32(8):1023–35.
Article CAS PubMed Google Scholar
Ye W, et al. The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: development and validation. Diabetes Technol Ther. 2015;17(10):701–11.
Article PubMed PubMed Central Google Scholar
Valentine WJP, et al. The prime diabetes model: novel methods for estimating long-term clinical and cost outcomes in type 1 diabetes mellitus. Value Health. 2016;20(7):985–91.
Willis M, Asseburg C, He J. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ. 2013;16(8):1007–21.
Willis M, et al. Validation of the economic and health outcomes model of type 2 diabetes mellitus (ECHO-T2DM). Pharmacoeconomics. 2017;35(3):375–96.
Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. BMC Health Serv Res. 2018;18(1):78–78.
Article PubMed PubMed Central Google Scholar
Laiteerapong N, et al. Individualized glycemic control for U.S. Adults with type 2 diabetes a cost-effectiveness analysis. Ann Intern Med. 2018;168(3):170–8.
Nguyen E, et al. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complic. 2018;32(2):210–5.
Shao H, et al. Novel risk engine for diabetes progression and mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). Pharmacoeconomics. 2018;36(9):1125–34.
留言 (0)